Pharmaceutical firm Lupin announced that it has received tentative approval from the US health regulator to market its generic version of Dolutegravir and Rilpivirine tablets used in treatment of HIV infection, in an exchange filing.
The tentative approval granted by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) of Dolutegravir and Rilpivirine tablets of strength 50 mg/25 mg, Lupin said in the filing.
The Dolutegravir and Rilpivirine tablets, 50 mg/25 mg had estimated annual sales of USD 666 million in the US, the company said citing IQVIA MAT September 2022 data.
Jaishankar Predicts Upswing In India–Europe Ties In 2026, Sees Key Role For Luxembourg
Poco M8 5G To Launch In India Today: Expected Price In India, Specifications
Jubilant FoodWorks Q3 FY26 Revenue Rises 13.4% To ₹2,439 Crore, Store Count At 3,594
'That's Extremely Stupid': Tottenham's Head Coach Thomas Frank Defends Himself After Arsenal-Branded Cup Gaffe Amid Spurs' Defeat; Video
